Verastem: Novel Drugs Targeting the Tumor Microenvironment

Verastem Inc. (NASDAQ: VSTM) is a clinical stage biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem's product candidates seek to treat cancer by targeting malignant cells both directly and through modulation of the tumor microenvironment. Our most advanced programs target the phosphoinositide-3-kinase (PI3K) and Focal Adhesion Kinase (FAK) pathways.




May 18, 2017
Verastem Announces Duvelisib Data Presentations at the 22nd Congress of the European Hematology Association

May 10, 2017
Verastem Reports First Quarter 2017 Financial Results

May 3, 2017
Verastem Announces Long Term Follow-up Data from the DYNAMO Study Selected for Oral Presentation at the 14th International Conference on Malignant Lymphoma



Major advances in cancer treatment have led to significant improvements in efficacy. However, this benefit does not extend to all patients. Challenges in the tumor microenvironment may both support tumor survival, and inhibit anti-tumor activity of cancer therapies and adaptive immune response.

Learn More »